Am J Transplant, Volume 16, Suppl 3 Archives - Page 71 of 180 - ATC Abstracts

2016 American Transplant Congress
Subnormothermic Machine Perfusion (SNMP) with a Novel Hemoglobin-Based Oxygen Carrier (HBOC) Solution for Ex Vivo Preservation in Vascularized Composite Allotransplantation (VCA).
S. Oksuz, R. Schweizer, M. Minervini, B. Banan, V. Gorantla, P. Fontes.
University of Pittsburgh, Pittsburgh.
Background: Improved preservation techniques could reduce ischemia-reperfusion injuries (IRI) and allow better matching and allocation of VCA grafts across wider distances. A novel SNMP system…
2016 American Transplant Congress
Transient Hepatitis B Core Positivity After Administration of IVIG for Desensitization (DES).
A. Nejad, A. Vo, J. Choi, S. Jordan.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA.
INTRODUCTION: IVIG has become an essential tool in the treatment of sensitized patients prior to solid organ transplantation and is routinely used to treat viral…
2016 American Transplant Congress
Gender Differences in Longitudinal eGFR of Living Kidney Donors in a Health Information Exchange.
M. Henderson,¹ T. McFarlane,¹ A. Massie,² D. Segev,² B. Dixon.^1,3
¹Indiana University, Indianapolis, IN; ²Johns Hopkins University, Baltimore, MD; ³Regenstrief Institute, Indianapolis, IN.
Background: The trajectory of post-donation eGFR in living donors is poorly described. Our objective was to explore the association between baseline donor characteristics and post-donation…
2016 American Transplant Congress
Rapid Emergence of CD28^null Cells Following Ex Vivo Restimulation Is Associated with Belatacept Resistant Rejection.
M. Cortes, S. Laurie, B. Sayed, M. Ford.
Emory Transplant Center, Atlanta, GA.
Numerous studies have implicated donor-reactive memory T cells in mediating costimulation blockade resistant rejection (CoBRR) following treatment with belatacept. In humans, these memory T cells…
2016 American Transplant Congress
The Impact of Treating Borderline Cellular Rejections.
R. Mustafa,¹ Y. Al Azzi,¹ J. Crew,¹ G. Dube,¹ H. Morris,¹ M. Chiles,¹ J. Chang,¹ H. Fernandez,¹ D. Cohen,¹ I. Batal,² E. Campenot,² S. Mohan.¹
¹Nephrology, Columbia University Medical Center, New York, NY; ²Pathology, Columbia University Medical Center, New York, NY.
Introduction: Histological findings that meet the criteria for Borderline rejection (BR) as defined by the Banff Classification are frequently seen. The clinical significance of a…
2016 American Transplant Congress
3D-FLM (First, Last, Max): A Novel Summative Measure of Hepatocellular Carcinoma (HCC) Tumor Burden Predicts HCC Recurrence After Liver Transplantation (LT).
E. Nordstrom,¹ J. Dodge,² J. Gralla,¹ K. Campbell,¹ C. Palmer,¹ S. Biggins.¹
¹Univ. Colorado, Aurora; ²UCSF, San Francisco.
Risk of recurrent HCC post-LT depends on tumor aggressiveness, pre-LT HCC burden and treatment response while waiting for LT. Standard measures of pre-LT HCC burden…
2016 American Transplant Congress
Minimum Graft Size Avoiding Small-for-Size Associated Early Graft Failure in Living Donor Liver Transplantation.
S. Marubashi,¹ H. Nagano,³ H. Eguchi,² H. Wada,² K. Umeshita,² Y. Doki,² M. Mori,² N. Sato,¹ T. Kimura,¹ A. Kenjyo,¹ M. Gotoh.¹
¹Regenerative Surgery, Fukushima Medical University, Fukushima, Japan; ²Surgery, Osaka University Graduate School of Medicine, Suita, Japan.
Small-for-size syndrome (SFSS) is a serious complication in living donor liver transplantation (LDLT). The aim of this study was to investigate the risk factors for…
2016 American Transplant Congress
Longitudinal Psychological Outcomes of Living Liver Donors.
Z. Butt,¹ M. Dew,² Q. Liu,³ M. Simpson,⁴ A. Smith,^3,5 J. Zee,³ B. Gillespie,⁵ S. Abbey,⁶ D. Ladner,¹ R. Weinreib,⁷ R. Fisher,⁸ S. Hafliger,⁹ N. Terrault,¹⁰ J. Burton,¹¹ A. DiMartini.²
¹Northwestern U, Chicago; ²U of Pittsburgh, Pittsburgh; ³Arbor Research Collaborative for Health, Ann Arbor; ⁴Lahey, Burlington; ⁵U of Michigan, Ann Arbor; ⁶U of Toronto, Toronto, Canada; ⁷U of Pennsylvania, Philadelphia; ⁸Virginia Commonwealth U, Richmond; ⁹Columbia U, New York; ¹⁰U of California at San Francisco, San Francisco; ¹¹U of Colorado, Denver.
Background: Living liver donors (LLD) are healthy adults donating a portion of their liver to a recipient in need. To justify the risk to LLD,…
2016 American Transplant Congress
Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA).
R. Knight,¹ S. Patel,¹ J. Loucks-DeVos,² S. Kuten,¹ A. Gaber.¹
¹Houston Methodist Hospital, Houston, TX; ²Kansas University Medical Center, Kansas City, KS.
Intravenous immune globulin (IVIG) may be beneﬁcial for pre-emptive treatment of de novo DSA in RTR without biopsy-proven acute rejection (AR). Herein, we present long-term…
2016 American Transplant Congress
Is Ketorolac Really Safe for Donor Nephrectomy?
K. Takahashi, K. Putchakayala, L. Malinzak, J. Denny, M. Abouljoud, D. Kim.
Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI.
Background. Ketorolac is a nonsteroidal anti-inflammatory drug used for postoperative pain management. The purpose of this study is to assess the impact of ketorolac after…